검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Chimeric Antigen Receptor T-cells (Chimeric Antigen Receptor T-cells) Fundamenta Therapeutics, Ltd.·Platinum-Resistant Ovarian Carcino… ORR 67% |
|---|---|
Overview Program | Chimeric Antigen Receptor T-cells |
Overview Company | Fundamenta Therapeutics, Ltd. |
Overview Modality | CGT |
Overview Target | Platinum-Resistant Ovarian Carcinoma |
Overview Indication | Leukemia, Acute Lymphocytic (ALL); Leukemia, Acute Myelogenous (AML) |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Mechanism | CAR-T and BsAb therapy, as an independent and alternative niche |
MoA Biomarker | Biomarker potential and therapeutic targeting to counteract drug resistance |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Beyond the chimeric antigen receptor T cells and bispecific antibody duopoly: ex vivo armed T cells for solid tumors.. While monoclonal antibodies (mAbs) continue to dominate the overall immunotherapy landscape, the field of T-cell-based therapeutics is rapidly evolving. Although chimeric antigen receptor T cells (CAR-T) and bispecific antibodies (BsAbs) currently represent the pillars of T-cell-d… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 67% |
Clinical ORR | 67% |
Clinical Result source | ClinicalTrials.gov NCT03704298 |
Clinical Data Tier / Score | A · 50 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 12일 (2일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Chimeric Antigen Receptor T-cells (Chimeric Antigen Receptor T-cells) Fundamenta Therapeutics, Ltd.·Platinum-Resistant Ovarian Carcino… ORR 67% |
|---|---|
Overview Program | Chimeric Antigen Receptor T-cells |
Overview Company | Fundamenta Therapeutics, Ltd. |
Overview Modality | CGT |
Overview Target | Platinum-Resistant Ovarian Carcinoma |
Overview Indication | Leukemia, Acute Lymphocytic (ALL); Leukemia, Acute Myelogenous (AML) |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Mechanism | CAR-T and BsAb therapy, as an independent and alternative niche |
MoA Biomarker | Biomarker potential and therapeutic targeting to counteract drug resistance |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Beyond the chimeric antigen receptor T cells and bispecific antibody duopoly: ex vivo armed T cells for solid tumors.. While monoclonal antibodies (mAbs) continue to dominate the overall immunotherapy landscape, the field of T-cell-based therapeutics is rapidly evolving. Although chimeric antigen receptor T cells (CAR-T) and bispecific antibodies (BsAbs) currently represent the pillars of T-cell-d… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 67% |
Clinical ORR | 67% |
Clinical Result source | ClinicalTrials.gov NCT03704298 |
Clinical Data Tier / Score | A · 50 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 12일 (2일 전) |
추천 비교
추천 비교